The estimated Net Worth of William Roland Mann is at least $475 Tisíc dollars as of 30 March 2022. Dr Mann owns over 6,200 units of NeuBase Therapeutics stock worth over $4,234 and over the last 4 years he sold NBSE stock worth over $0. In addition, he makes $470,398 as Chief Operating Officer at NeuBase Therapeutics.
Sign up
Dr D NBSE stock SEC Form 4 insiders trading
Dr has made over 2 trades of the NeuBase Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 6,200 units of NBSE stock worth $11,904 on 30 March 2022.
The largest trade he's ever made was buying 6,200 units of NeuBase Therapeutics stock on 30 March 2022 worth over $11,904. On average, Dr trades about 2,240 units every 68 days since 2020. As of 30 March 2022 he still owns at least 11,200 units of NeuBase Therapeutics stock.
You can see the complete history of Dr Mann stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. William Roland Mann MBA, Ph.D. biography
Dr. William Roland Mann MBA, Ph.D. is the Chief Operating Officer at NeuBase Therapeutics.
What is the salary of Dr D?
As the Chief Operating Officer of NeuBase Therapeutics, the total compensation of Dr D at NeuBase Therapeutics is $470,398. There are 7 executives at NeuBase Therapeutics getting paid more, with Dietrich Stephan having the highest compensation of $3,677,280.
How old is Dr D?
Dr D is 61, he's been the Chief Operating Officer of NeuBase Therapeutics since . There are 1 older and 9 younger executives at NeuBase Therapeutics. The oldest executive at NeuBase Therapeutics, Inc. is Franklyn Prendergast, 75, who is the Independent Director.
What's Dr D's mailing address?
William's mailing address filed with the SEC is C/O 350 TECHNOLOGY DRIVE, FOURTH FLOOR, , PITTSBURGH, PA, 15219.
Insiders trading at NeuBase Therapeutics
Over the last 5 years, insiders at NeuBase Therapeutics have traded over $713,184 worth of NeuBase Therapeutics stock and bought 177,514 units worth $548,788 . The most active insiders traders include Dov A Md Goldstein, Dietrich A Stephan a Samuel Backenroth. On average, NeuBase Therapeutics executives and independent directors trade stock every 56 days with the average trade being worth of $37,929. The most recent stock trade was executed by Corp Symetryx on 14 September 2023, trading 282,445 units of NBSE stock currently worth $375,652.
What does NeuBase Therapeutics do?
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
What does NeuBase Therapeutics's logo look like?
Complete history of Dr Mann stock trades at NeuBase Therapeutics
NeuBase Therapeutics executives and stock owners
NeuBase Therapeutics executives and other stock owners filed with the SEC include:
-
Dietrich Stephan,
President, Chief Executive Officer, Director -
Sam Backenroth,
Chief Financial Officer, Treasurer, Secretary -
Eric Richman,
Independent Director -
Franklyn Prendergast,
Independent Director -
Diego Miralles,
Independent Director -
Dov Goldstein,
Independent Director -
Dr. Dietrich A. Stephan Ph.D.,
Founder, Pres, CEO, Chairman & Interim CFO -
Dr. William Roland Mann MBA, Ph.D.,
Chief Operating Officer -
Samuel Backenroth,
CFO, Treasurer & Sec. -
Dan Ferry,
IR Contact Officer -
William Mann,
Chief Operating Officer -
Dr. Sandra Rojas-Caro M.D.,
Chief Medical Officer -
Shannon McCarthy,
Chief People Officer -
Alan Scrivner J.D.,
VP of IP & Legal -
Dr. Anthony Rossomando Ph.D.,
Chief Technology Officer -
Dr. Robert Zamboni Ph.D.,
Chief of Preclinical Devel. & Member of Scientific Advisory Board -
Dr. Robert Friedlander M.D.,
Consulting Chief Medical Officer -
Dr. Curt Bradshaw Ph.D.,
Chief Scientific Officer -
Eric J Ende,
Director -
Curt Bradshaw,
Chief Scientific Officer -
Gerald J Mc Dougall,
Director -
Kianoush Motesharei,
See Remarks -
Todd P. Branning,
Chief Financial Officer -
Corp Symetryx,
10% owner -
Dietrich A Stephan,
Founder and CEO